28 July 2016 - The cost and affordability of new cancer drugs are major factors contributing to a stark divide in drug availability between eastern and western Europe, a European survey has revealed.

The survey showed that the poorest drug availability is in countries with lower levels of economic development, and is largely related to the cost of targeted drugs approved in the past 10 years.

Read The Lancet editorial